Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $2.95 million. The enterprise value is -$872,243.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
Earnings Date | May 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
REVB has 905,228 shares outstanding. The number of shares has increased by 1,260.42% in one year.
Current Share Class | 905,228 |
Shares Outstanding | 905,228 |
Shares Change (YoY) | +1,260.42% |
Shares Change (QoQ) | +180.32% |
Owned by Insiders (%) | 5.09% |
Owned by Institutions (%) | 3.70% |
Float | 859,183 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.07 |
P/TBV Ratio | 0.98 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61
Current Ratio | 3.61 |
Quick Ratio | 3.40 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -233.26% and return on invested capital (ROIC) is -82.65%.
Return on Equity (ROE) | -233.26% |
Return on Assets (ROA) | -54.68% |
Return on Invested Capital (ROIC) | -82.65% |
Return on Capital Employed (ROCE) | -283.54% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.60M |
Employee Count | 9 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.11% in the last 52 weeks. The beta is 0.19, so REVB's price volatility has been lower than the market average.
Beta (5Y) | 0.19 |
52-Week Price Change | -90.11% |
50-Day Moving Average | 3.05 |
200-Day Moving Average | 9.41 |
Relative Strength Index (RSI) | 56.64 |
Average Volume (20 Days) | 50,045 |
Short Selling Information
The latest short interest is 69,578, so 7.69% of the outstanding shares have been sold short.
Short Interest | 69,578 |
Short Previous Month | 118,470 |
Short % of Shares Out | 7.69% |
Short % of Float | 8.10% |
Short Ratio (days to cover) | 0.52 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -8.17M |
Pretax Income | -15.90M |
Net Income | -14.41M |
EBITDA | -8.14M |
EBIT | -8.17M |
Earnings Per Share (EPS) | -$36.26 |
Full Income Statement Balance Sheet
The company has $3.70 million in cash and n/a in debt, giving a net cash position of $3.70 million or $4.09 per share.
Cash & Cash Equivalents | 3.70M |
Total Debt | n/a |
Net Cash | 3.70M |
Net Cash Per Share | $4.09 |
Equity (Book Value) | 2.88M |
Book Value Per Share | 2.97 |
Working Capital | 2.84M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$18.28 million and capital expenditures $1, giving a free cash flow of -$18.28 million.
Operating Cash Flow | -18.28M |
Capital Expenditures | 1 |
Free Cash Flow | -18.28M |
FCF Per Share | -$20.19 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |